Gilead Sciences, Inc. (NASDAQ:GILD) gapped down prior to trading on Monday . The stock had previously closed at $80.19, but opened at $77.83. Gilead Sciences shares last traded at $75.16, with a volume of 14,664,666 shares trading hands.
Several equities analysts recently weighed in on the stock. BMO Capital Markets cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and set a $79.00 price target on the stock. in a research report on Monday, April 20th. Raymond James cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating in a research report on Friday, May 1st. SunTrust Banks raised shares of Gilead Sciences from a “sell” rating to a “hold” rating and raised their price target for the company from $70.00 to $73.00 in a research report on Tuesday, May 26th. TheStreet raised shares of Gilead Sciences from a “c” rating to a “b-” rating in a research report on Friday, February 21st. Finally, Cowen reissued a “buy” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Monday, April 13th. Five research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $78.96.
The company has a current ratio of 3.04, a quick ratio of 2.92 and a debt-to-equity ratio of 1.00. The company has a market cap of $97.63 billion, a P/E ratio of 19.32, a PEG ratio of 3.52 and a beta of 0.68. The business’s fifty day moving average is $77.39 and its 200 day moving average is $70.48.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Friday, June 12th will be paid a $0.68 dividend. The ex-dividend date of this dividend is Thursday, June 11th. This represents a $2.72 dividend on an annualized basis and a yield of 3.62%. Gilead Sciences’s dividend payout ratio is 44.30%.
In other news, EVP Brett A. Pletcher sold 2,950 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $75.55, for a total transaction of $222,872.50. Following the completion of the transaction, the executive vice president now directly owns 17,594 shares in the company, valued at approximately $1,329,226.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 13,210 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the transaction, the executive vice president now owns 27,204 shares of the company’s stock, valued at $2,155,372.92. The disclosure for this sale can be found here. Insiders sold a total of 50,144 shares of company stock valued at $3,931,225 over the last quarter. 0.13% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in GILD. Pin Oak Investment Advisors Inc. purchased a new position in shares of Gilead Sciences during the 4th quarter valued at $26,000. Baldwin Brothers Inc. MA grew its position in shares of Gilead Sciences by 63.3% during the 1st quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 136 shares in the last quarter. IndexIQ Advisors LLC purchased a new position in shares of Gilead Sciences during the 4th quarter valued at $28,000. Engrave Wealth Partners LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth $29,000. Finally, Bainco International Investors bought a new stake in shares of Gilead Sciences during the 1st quarter worth $29,000. Hedge funds and other institutional investors own 80.15% of the company’s stock.
About Gilead Sciences (NASDAQ:GILD)
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: What are economic reports?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.